Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron

As recommended by most recent antiemetic guidelines, the optimal prophylaxis of chemotherapy-induced nausea and vomiting (CINV) requires the combination of 5-HT3 receptor antagonist (RA) with an NK1-RA. Moreover, the major predictors of acute and delayed CINV include: young age, female sex, platinum...

Descripción completa

Detalles Bibliográficos
Autor principal: Lorusso, Vito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907706/
https://www.ncbi.nlm.nih.gov/pubmed/27354807
http://dx.doi.org/10.2147/TCRM.S89215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907706/
https://www.ncbi.nlm.nih.gov/pubmed/27354807
http://dx.doi.org/10.2147/TCRM.S89215

Ejemplares similares